Zacks Research raised its fourth-quarter 2026 earnings per share (EPS) estimate for Bristol-Myers Squibb to $1.64, up from $1.50. The firm also increased its full-year 2027 EPS estimate for the biopharmaceutical company.
This upgraded forecast follows the U.S. Food and Drug Administration's (FDA) accelerated approval of ZENBEXUS™ (iberdomide) on August 13, 2026. ZENBEXUS™, a first-in-class CELMoD, treats adult patients with multiple myeloma who have received at least one prior line of therapy. The approval strengthens the company's oncology portfolio.